Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

BusinessWire_EN 
0 0 09.11.20
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
 

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that management will present at two investor conferences in November.

  • Credit Suisse 29th Annual Virtual Healthcare Conference
    • Date: Wednesday, November 11, 2020
    • Time: 9:30am Eastern Time
    • Participants: Mary Anne Heino, President and Chief Executive Officer and Bob Marshall, Chief Financial Officer and Treasurer
  • Jefferies Virtual London Healthcare Conference
    • Date: Tuesday, November 17, 2020
    • Time: 7:20am Eastern Time
    • Participant: Bob Marshall, Chief Financial Officer and Treasurer

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005984/en/

Lantheus Holdings Inc Stock

€108.95
0.370%
The Lantheus Holdings Inc stock is trending slightly upwards today, with an increase of €0.40 (0.370%) compared to yesterday's price.

Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!